Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-02-01 @ 4:06 PM
Study NCT ID:
NCT06672705
Status:
RECRUITING
Last Update Posted:
2025-08-19
First Post:
2024-11-01
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders
Sponsor:
Timothy Voorhees
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder | View |
| None | EBV-Related Post-Transplant Lymphoproliferative Disorder | View |
| None | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | View |
| None | Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder | View |
| None | Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder | View |
| None | Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder | View |
Keywords: